Text Size

Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by North Texas Veterans Healthcare System.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
North Texas Veterans Healthcare System
ClinicalTrials.gov Identifier:
NCT01121458
First received: February 2, 2010
Last updated: May 10, 2010
Last verified: January 2010
History of Changes
  Purpose

Pulmonary arterial hypertension (PAH) is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery (PA) rises above normal levels and may become life threatening. PAH is frequently misdiagnosed and has often progressed to late stage by the time it is accurately diagnosed. PAH has been historically chronic and incurable with a poor survival rate. However, new treatments are available which have significantly improved prognosis. Right-heart catheterization (RHC) is the most accurate and useful test for PAH, and the only test that directly measures the pressure inside the PA. It is performed in all patients at least once, to get a definitive diagnosis of PAH.

The most commonly used medication for this purpose is intravenous nitroprusside, however this medication in about 25-30% of patients is not well tolerated as it cause fast heart rates, which is not well tolerated by patients with pulmonary hypertension and/or heart failure. The CARVE study assesses the effect of Clevidipine, an ultra-short acting vasoselective calcium antagonist, on pulmonary vascular resistance (PVR) and its utility for pulmonary vasoreactivity testing during right heart catheterization (RHC) of patients with pulmonary hypertension (PAH).


Condition Intervention Phase
Hypertension, Pulmonary
 Drug: Clevidipine
 Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE)

Resource links provided by NLM:

Drug Information available for: Clevidipine
U.S. FDA Resources

Further study details as provided by North Texas Veterans Healthcare System:

Primary Outcome Measures:
  • Percent reduction in PVR with clevidipine in (1) nitroprusside responders and (2) patients with indeterminate nitroprusside reactivity tests [ Time Frame: During right heart catheterization (1-2 hours) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Efficacy/ safety measured by % reduction in PVR with clevidipine in patients with indeterminate reactivity tests & total study population;%patients with successful 20% reduction in PVR; SAE & adverse hemodynamic response to clevidipine during procedure [ Time Frame: During right heart catheterization (1-2 hrs) ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 20
Study Start Date: September 2009
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Clevidipine
    The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP< 80 mmHg), hypertension (SBP>150 mmHg), tachycardia (120 beats per minute), bradycardia (<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
    Other Name: Cleviprex
Detailed Description:

CARVE is a Phase 4 open-label descriptive observational trial in PAH patients undergoing invasive vasoreactivity testing in the cath lab at the Dallas VA Medical Center. Patients clinically indicated for RHC and assessment of pulmonary artery vasoreactivity will be enrolled if they meet the inclusion/exclusion criteria. The study will involve the following tests:

  1. Performance of clinically indicated RHC with assessment of pulmonary hypertension and pulmonary vascular resistance (PVR).
  2. Performance of clinically indicated pulmonary vasoreactivity assessment with IV Nitroprusside (standard of care)
  3. For patients who are responsive to Nitroprusside, or those who have an inconclusive result because of intolerability to Nitroprusside, pulmonary vasoreactivity assessment with study drug (IV) will be conducted.
  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provide written informed consent before initiation of any study related procedures.
  • 21 years of age or older
  • Referred for clinically indicated pulmonary vascular resistance assessment
  • Presence of pulmonary hypertension by non-invasive testing
  • Patients referred for RHC and vasoreactivity testing

Exclusion Criteria:

  • Patient with baseline SBP < 100 mmHg
  • Patient with HR>120 beats/minute
  • Patients with severe or valvular heart disease
  • Patients with an acute coronary syndrome
  • Patients with a creatinine clearance < 30 ml/min
  • Patients with class IV congestive heart failure
  • Patients with platelet count < 100,000 per cc3
  • Patients with hemoglobin < 10g/dl
  • Patient with INR > 1.5
  • Patients with positive pregnancy test - women between 21 and 60 years of age
  • Patients with known or suspected allergy to study drug or study drug components, including allergy to soybeans, soy products, eggs, or egg products
  • Patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia
  • Patients with contraindications to the use of IV nitroprusside
  • Patients with diagnosed or suspected intra-cardiac or systemic arteriovenous shunts
  • Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 3 months of randomization.
  • Other medical conditions that, in the opinion of the investigator, preclude participation in the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01121458

Contacts
Contact: Subhash Banerjee, MD 214-857-1608 Subhash.Banerjee@va.gov
Contact: Preeti Kamath 214-857-0305 Preeti.Kamath@va.gov

Locations
United States, Texas
VA North Texas Health Care System Recruiting
Dallas, Texas, United States, 75216
Principal Investigator: Subhash Banerjee, MD            
Sub-Investigator: Emanouil Brilakis, MD,PhD            
Sponsors and Collaborators
North Texas Veterans Healthcare System
Investigators
Principal Investigator: Subhash Banerjee, MD North Texas Veterans Healthcare System
  More Information

No publications provided

Responsible Party: Subhash Banerjee,MD, VA North Texas Health Care System
ClinicalTrials.gov Identifier: NCT01121458     History of Changes
Other Study ID Numbers: Dallas VA #09-041
Study First Received: February 2, 2010
Last Updated: May 10, 2010
Health Authority: United States: Federal Government

Keywords provided by North Texas Veterans Healthcare System:
pulmonary artery
vascular resistance

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
 Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 23, 2013